The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Glasdegib as maintenance therapy in AML and MDS
Daniel Pollyea, MD, MS, of the University of Colorado, Denver, CO, discusses the results of a study evaluating glasdegib, a hedgehog inhibitor, as maintenance therapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients at high-risk for post-allogeneic stem cell transplant relapse. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
